Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective.

In this severe asthma population from a Canadian Allergist's practice, one-third of individuals qualified for all currently available biologics. 41-78% were eligible for at least one mAb. Patients were most likely to be eligible for mepolizumab. Objective assessments to determine asthma phenotype, along with further characterization of safety profiles will lead to further advances in asthma management.